RCAN1,, HL60, calcineurin, NFAT
|
|
- Erika Walters
- 5 years ago
- Views:
Transcription
1 RCAN1 calcineurin RCAN1 1) 2) calcineurin-nfat RCAN1 RCAN1 RCAN1 is involved in the regulation of cell functions including inhibition of calcineurin. In this study, we found that RCAN1 is extraordinarily expressed in leukemia cells. Furthermore, we revealed that RCAN1 is important for cell growth, particularly under undesirable conditions of low serum concentration. In leukemia cells, calcineurin-nfat signaling has been shown to be one of the targets of RCAN1. We also identified several molecules, which could directly bind with RCAN RCAN1,, HL60, calcineurin, NFAT 1. (AML) AML RCAN1 Ca 2+ /Calmodulin calcineurin NF-AT NF-kB Down RCAN1 calcinuirin
2 RCAN1 Down RCAN1 RCAN1 RCAN1 RCAN1 2. RCAN1 3. (1) RCAN1 1(AML) (THP-1HL60U937) (Jurkat, Raji) (CML)(KCL22K562 KU812) (RPMI8226U266) RNA Superscript II reverse transcriptase cdna Reverse transcriptase-polymerase chain reaction(rt-pcr) RCAN1 mrna RCAN1 Western Blot RCAN1 2AML CML RNA RCAN1 mrna RT-PCR real-time PCR real-time PCR ABI PRISM 7700 system (2) RCAN1 FACSaria (Becton Dickinson) FACS CD34 CD38CD14CD16CD33 RCAN1 mrna RT-PCR real-time PCR (3) AML RCAN1 pll3.7 3 RCAN1 shrna RCAN1 shrna HL60 RCAN1 shrna RCAN1 Western Blot RCAN1 (4) RCAN1 Calcineurin-NFAT signaling RCAN1 shrna HL60 RCAN1 calcineurin NFAT4 Western Blot RCAN1 calcineurin cyclosporine A (5) RCAN1 RPMI8226 U266 RCAN1 shrna (6) Two-hybrid screening RCAN1 RCAN1 cdna Bait K562 Prey Yeast two-hybrid screening 4. (1) RCAN1 RCAN1 mrna RT-PCR RCAN1 RCAN1-1 Western Blot
3 (2) AML CML RCAN1 6 AML RCAN1 mrna 1%RCAN1 a) b) RCAN1 c)cleaved caspases cleaved PARP CML RCAN1 (3) RCAN1 FACS CD34+CD38- CD34+CD38+ CD33+CD14-CD16- CD33+CD14+ CD33+CD16+ RCAN1 RT-PCR real-time PCR RCAN1 CML RCAN1 (5) Calcineurin-NFAT signaling RCAN1 HL60 RCAN1 shrna a)calcineurin b) NFAT4 c) NFAT4 (4) RCAN1 RCAN1 shrna HL60 IL-3 32D RCAN1 L-3
4 HL60 RCAN1 calcineurin NFAT4 calcineurin cyclosporine A RCAN1 RCAN1 calcineurin RCAN1 (6) RCAN1 RPMI8226 U266 RT-PCR RCAN1-1 CD138 RCAN RCAN1 RCAN1 (8) RCAN1-2768bp RCAN1 pgl4.17[luc2/neo] deletion mutants KCL bp -866 bp RCAN1 (7) RCAN1 RPMI8226 RCAN1 shrna U266 PLL3.7 RPMI8226 U bp-866 bp -459bp -249bp TGIFHNF-4 USF RCAN1 (9) RACN1 RCAN1 cdna Bait K562 Prey Yeast two-hybrid screening
5 HINT1, HINT2 LINT1 RCAN1 in vitro translation pmx RCAN (1) Nagai, T., Ohmine, K., Fujiwara, S., Uesawa, M., Sakurai, C., and Ozawa, K.: Combination of tipifarnib and rapamycin synergistically inhibits the growth of leukemia cells and overcomes resistance to tipifarnib via alteration of cellular signaling pathways. Leukemia Res. 34: , DOI: /j.leukres. (2) Nagai, T., Takeuchi, J., Usui, N : Imatinib for Newly Diagnosed Chronic-Phase Chronic Myeloid Leukemia: Results of a Prospective Study in Japan. Int J Hematol. 92: , DOI: /s x. (3) Tatara, R., Nagai, T., Kobayashi, H., Hatano, K., Suzuki, T., Muroi, K., and Ozawa, K. AA amyloidosis associated with macroglobulinemia. (Letter) Int J Hematol. 92: , DOI: /s z. (4) Sato, K., Ozaki, K., Matsuyama, T., Ohmine, K., Suzuki, T., Mori, M., Nagai, T., Muroi, K., and Ozawa, K.: Incidental carcinomas detected by PET/CT scans in patients with malignant lymphoma. Int J Hematol. 92: , DOI: /s x. (5) Yoshida, K., Nagai, T., Ohmine, K., Uesawa, M., Sripayap, P., Ishida, Y., and Ozawa, K.: Vincristine potentiates the anti-proliferative effect of an aurora kinase inhibitor, VE-465, in myeloid leukemia cells. Biochem. Pharmcol. 82: , DOI: /j.bcp. (6) Kikuchi, Y., Kume, A., Urabe, M., Mizukami, H., Suzuki, T., Ozaki, K., Nagai, T., and Ozawa, K.: Reciprocal upregulation of Notch signaling molecules in hematopoietic progenitor and mesenchymal stromal cells. J Stem Cells Regenerative Med. 7: 61-68, htm (7) Meguro, A., Nagai, T., Ozawa, K : Rituximab plus 70% cyclophosphamide, doxorubicin, vincristine and prednisone for Japanese patients with diffuse large B-cell lymphoma aged 70 years and older. Leuk Lymphoma. 53: 43-49, DOI: / (8) Oka, S., Nagai, T., Hanafusa, T. 910 : Prediction of progression from refractory cytopenia with unilineage dysplasia by analysis of bone marrow blast cell composition. J Clin. Exp. Hematop. 52: 63-66, DOI: (9) Sato, K., Nagai, T., Izumi, T., Ohmine, K., Ozaki, K., Muroi, K., and Ozawa, K.: Rituximab-induced interstitial pneumonia due to CD8-positive T-cell infiltration. Acta Haematologica. 128: , DOI: / (10) Kobayashi, H., Nagai, T., Muroi, K. 8 9 : Autologous hematopoietic recovery with aberrant antigen expression after allogeneic bone marrow transplantation. J Clin. Exp. Hematop. 52: 81-83, DOI: (11) Nagai, T., Suzuki, T., Komatsu, N., Hosokawa, K., Nakao, S., and Ozawa, K.: Alteration of chromosome 13 abnormalities after therapeutic heamatopoiesis recovery in myelodysplastic syndrome. Open J Hematol.
6 3-7, DOI: /ojhmt_3_1_ (1) Fujiwara, S.: Extraordinary expression of RCAN1 Crucial to leukemia progression (2) Fujiwara, S.: Crucial role of RCAN1 in leukemia progression (3) Uesawa, M.: Cloning of 5-azacitidine-resistant acute myeloid leukemia cell lines, THP-1/AR and HL60/AR. The 2 nd JSH International Symposium, Nagasaki, 2011 (4) Sripayap, P.: Cloning and characterization of 5-azacitidine-resistant human AML cell lines, THP-1/AR and HL60/A (5) Sripayap, P.: Histone deacetylase inhibitor romidepsin overcomes AZA-resistance in AZA-resistant cell lines. The 3 rd JSH International Symposium, Kawagoe, Japan, 2012 (6) Sripayap, P.: Overcoming resistance to 5-azacytidine in acute myeloid leukemia. The 54th Annual Meeting of American Society for Hematology, Atlanta, USA, 2012 (7) Kobayashi, H.: Analysis of primary small intestinal lymphoma diagnosed with double-balloon endoscopy (8) Sripayap, P.: Histone deacetylase inhibitor romidepsin overcomes 5-azacytidine (AZA) resistance (FUJIWARA SHIN-ICHIRO) (1) NAGAI TADASHI (2) (3) OHMINE KEN
Flow cytometric evaluation of endoscopic biopsy specimens from patients with gastrointestinal tract B-cell lymphoma: a preliminary report
Jichi Medical University Journal Flow cytometric evaluation of endoscopic biopsy specimens from patients with gastrointestinal tract B-cell lymphoma: a preliminary report Satoko Oka,, Kazuo Muroi,, Kazuya
More informationMyelodysplastic Syndromes: Hematopathology. Analysis of SHIP1 as a potential biomarker of Disease Progression
Myelodysplastic Syndromes: Hematopathology. Analysis of SHIP1 as a potential biomarker of Disease Progression Carlos E. Bueso-Ramos, M.D., Ph.D Department of Hematopathology The University of Texas M.
More informationPeking University People's Hospital, Peking University Institute of Hematology
Qian Jiang, M.D. Peking University People's Hospital, Peking University Institute of Hematology No. 11 Xizhimen South Street, Beijing, 100044, China. Phone number: 86-10-66583802 Mobile: 86-13611115100
More informationCommissioning policies agreed by PCTs in Yorkshire and the Humber at Board meeting of YH SCG on December
Commissioning policies agreed by PCTs in Yorkshire and the Humber at Board meeting of YH SCG on December 17 2010. 32/10 Imatinib for gastrointestinal stromal tumours (unresectable/metastatic) (update on
More informationa resource for physicians Recommended Referral Timing for Stem Cell Transplant Evaluation
a resource for physicians Recommended Referral Timing for Stem Cell Transplant Evaluation This resource has been developed to help guide you regarding the appropriate timing and conditions for a referral
More informationStem Cell Transplantation for Severe Aplastic Anemia
Number of Transplants 10/24/2011 Stem Cell Transplantation for Severe Aplastic Anemia Claudio Anasetti, MD Professor of Oncology and Medicine Chair, Blood and Marrow Transplant Dpt Moffitt Cancer Center
More informationTRANSPARENCY COMMITTEE OPINION. 14 February 2007
The legally binding text is the original French version TRANSPARENCY COMMITTEE OPINION 14 February 2007 GLIVEC 100 mg, capsule B/120 capsules (CIP: 358 493-5) GLIVEC 100 mg, capsule B/180 capsules (CIP:
More informationMolecular Detection of BCR/ABL1 for the Diagnosis and Monitoring of CML
Molecular Detection of BCR/ABL1 for the Diagnosis and Monitoring of CML Imran Mirza, MD, MS, FRCPC Pathology & Laboratory Medicine Institute Sheikh Khalifa Medical City, Abu Dhabi, UAE. imirza@skmc.ae
More informationMYELODYSPLASTIC SYNDROMES
MYELODYSPLASTIC SYNDROMES Babak Tamizi Far MD. Assistant professor of internal medicine Al-zahra university hospital, Isfahan university of medical sciences Key Features ESSENTIALS OF DIAGNOSIS Cytopenias
More informationRole of FISH in Hematological Cancers
Role of FISH in Hematological Cancers Thomas S.K. Wan PhD,FRCPath,FFSc(RCPA) Honorary Professor, Department of Pathology & Clinical Biochemistry, Queen Mary Hospital, University of Hong Kong. e-mail: wantsk@hku.hk
More informationBL-8040: BEST-IN-CLASS CXCR4 ANTAGONIST FOR TREATMENT OF ONCOLOGICAL MALIGNANCIES. Overview and Mechanism of Action Dr.
BL-8040: BEST-IN-CLASS CXCR4 ANTAGONIST FOR TREATMENT OF ONCOLOGICAL MALIGNANCIES Overview and Mechanism of Action Dr. Leah Klapper, CSO 88 BL-8040: Novel CXCR4 Antagonist For Hematological Cancers Indications:
More informationOpen Journal of Oncology & Hematology
Open Journal of Oncology & Hematology Research Article Peripheral Blood Wilms Tumor Gene mrna as a Parameter to Predict Hematological Responses and Prognoses in Patients with Myelodysplastic Syndromes
More informationRecommended Timing for Transplant Consultation
REFERRAL GUIDELINES Recommended Timing for Transplant Consultation Published jointly by the National Marrow Donor Program /Be The Match and the American Society for Blood and Marrow Transplantation BeTheMatchClinical.org
More informationMyeloproliferative Disorders - D Savage - 9 Jan 2002
Disease Usual phenotype acute leukemia precursor chronic leukemia low grade lymphoma myeloma differentiated Total WBC > 60 leukemoid reaction acute leukemia Blast Pro Myel Meta Band Seg Lymph 0 0 0 2
More informationMyelodysplasia/Myeloproliferative Neoplasms (MDS/MPN) Post-HCT Data
Instructions for Myelodysplasia/Myeloproliferative Neoplasms (MDS/MPN) Post-HCT Data (Form 2114) This section of the CIBMTR Forms Instruction Manual is intended to be a resource for completing the Myelodysplasia/Myeloproliferative
More informationSystematic Reviews in Hematological Malignancies
Systematic Reviews in Hematological Malignancies Pia Raanani, MD Davidoff Cancer Center Rabin Medical Center, Israel 1 2 Disorder CHMG Systematic review* Title Protocol Full Review Myelodysplastic syndrome
More informationTasigna. Tasigna (nilotinib) Description
Federal Employee Program 1310 G Street, N.W. Washington, D.C. 20005 202.942.1000 Fax 202.942.1125 5.21.77 Subject: Tasigna Page: 1 of 6 Last Review Date: March 16, 2018 Tasigna Description Tasigna (nilotinib)
More informationTasigna. Tasigna (nilotinib) Description
Federal Employee Program 1310 G Street, N.W. Washington, D.C. 20005 202.942.1000 Fax 202.942.1125 5.21.77 Subject: Tasigna Page: 1of 5 Last Review Date: September 15, 2017 Tasigna Description Tasigna (nilotinib)
More information5/9/2018. Bone marrow failure diseases (aplastic anemia) can be cured by providing a source of new marrow
5/9/2018 or Stem Cell Harvest Where we are now, and What s Coming AA MDS International Foundation Indianapolis IN Luke Akard MD May 19, 2018 Infusion Transplant Conditioning Treatment 2-7 days STEM CELL
More informationTransplant Booklet D Page 1
Booklet D Pretest Correct Answers 4. (A) is correct. Technically, performing a hematopoietic stem cell transplant is one of the simplest transplantation procedures. The hematopoietic stem cells are infused
More informationTHE USE OF WT1-QPCR TO MEASURE AND DETECT MINIMAL RESIDUAL DISEASE IN ACUTE MYELOID LEUKEMIA. Ava Greco
THE USE OF WT1-QPCR TO MEASURE AND DETECT MINIMAL RESIDUAL DISEASE IN ACUTE MYELOID LEUKEMIA Ava Greco REVIEW OF LITERATURE What is Leukemia? Abnormal growth of cells in the blood stream Progresses rapidly
More informationTARGETED THERAPY FOR CHILDHOOD CANCERS
TARGETED THERAPY FOR CHILDHOOD CANCERS AZIZA SHAD, MD AMEY DISTINGUISHED PROFESSOR OF PEDIATRIC HEMATOLOGY ONCOLOGY, BLOOD AND MARROW TRANSPLANTATION LOMBARDI CANCER CENTER GEORGETOWN UNIVERSITY HOSPITAL
More informationReduced-intensity Conditioning Transplantation
Reduced-intensity Conditioning Transplantation Current Role and Future Prospect He Huang M.D., Ph.D. Bone Marrow Transplantation Center The First Affiliated Hospital Zhejiang University School of Medicine,
More informationSunitinib, an orally available receptor tyrosine kinase inhibitor, induces monocytic
Sunitinib, an orally available receptor tyrosine kinase inhibitor, induces monocytic differentiation of acute myeogenouse leukemia cells that is enhanced by 1,25-dihydroxyviatmin D 3. To the Editor: Sunitinib,
More informationIntracellular staining of granzyme B and perforin for diagnosis of acute graft-versus-host disease
Jichi Medical University Journal Original Article Intracellular staining of granzyme B and perforin for diagnosis of acute graft-versus-host disease Haruko Matsu, Katsutoshi Ozaki, Raine Tatara, Satoko
More informationscreening procedures Disease resistant to full-dose imatinib ( 600 mg/day) or intolerant to any dose of imatinib
Table S1. Study inclusion and exclusion criteria Inclusion criteria Aged 18 years Signed and dated informed consent form prior to protocol-specific screening procedures Cytogenetic- or PCR-based diagnosis
More informationAML IN OLDER PATIENTS Whenever possible, intensive induction therapy should be considered
AML IN OLDER PATIENTS Whenever possible, intensive induction therapy should be considered Charles A. Schiffer, M.D. Karmanos Cancer Institute Wayne State University School of Medicine Detroit, MI WHY ARE
More informationArsenic Trioxide: An Emerging Therapy for Multiple Myeloma
Arsenic Trioxide: An Emerging Therapy for Multiple Myeloma NIKHIL C. MUNSHI University of Arkansas for Medical Science, Little Rock, Arkansas, USA Key Words. Arsenic trioxide Multiple myeloma Antiangiogenesis
More informationTHE LEUKEMIAS. Etiology:
The Leukemias THE LEUKEMIAS Definition 1: malignant transformation of the pluripotent stem cell, successive expansion of the malignant clone from the bone marrow to the tissues Definition 2: Heterogenous
More informationBC Cancer Protocol Summary for Therapy of Acute Myeloid Leukemia Using azacitidine and SORAfenib
BC Cancer Protocol Summary for Therapy of Acute Myeloid Leukemia Using azacitidine and SORAfenib Protocol Code Tumour Group Contact Physician ULKAMLAS Leukemia/BMT Dr. Donna Hogge ELIGIBILITY: Acute myeloid
More informationBLOOD AND LYMPH CANCERS
BLOOD AND LYMPH CANCERS 2 Blood and Lymph Cancers Highlights from the 2009 Annual Meeting of the American Society of Clinical Oncology Edited by Kenneth C. Anderson, MD Harvard Medical School and Dana-Farber
More informationONE STEP MULTIPLEX RT-PCR FOR BCRlABL GENE IN MALAY PATIENTS DIAGNOSED AS LEUKAEMIA
ONE STEP MULTIPLEX RT-PCR FOR BCRlABL GENE IN MALAY PATIENTS DIAGNOSED AS LEUKAEMIA 1Rosline H, 1Majdan R, 1Wan Zaidah A, 1Rapiaah M, 1Selamah G, 2A A Baba, 3D M Donald 1Department of Haematology, 2Department
More informationLYMPHOMA Joginder Singh, MD Medical Oncologist, Mercy Cancer Center
LYMPHOMA Joginder Singh, MD Medical Oncologist, Mercy Cancer Center Lymphoma is cancer of the lymphatic system. The lymphatic system is made up of organs all over the body that make up and store cells
More informationMeeting Report. From December 8 to 11, 2012 at Atlanta, GA, U.S.A
Meeting Report Affiliation Department of Transfusion Medicine and Cell Therapy Name Hisayuki Yao Name of the meeting Period and venue Type of your presentation Title of your presentation The 54 th Annual
More informationCorporate Medical Policy. Policy Effective February 23, 2018
Corporate Medical Policy Genetic Testing for FLT3, NPM1 and CEBPA Mutations in Acute File Name: Origination: Last CAP Review: Next CAP Review: Last Review: genetic_testing_for_flt3_npm1_and_cebpa_mutations_in_acute_myeloid_leukemia
More informationTreatment of Waldenström s Macroglobulinemia Mayo Consensus
Treatment of Waldenström s Macroglobulinemia Mayo Consensus Scottsdale, Arizona Rochester, Minnesota Jacksonville, Florida Mayo Clinic College of Medicine Mayo Clinic Comprehensive Cancer Center Mayo Clinic
More informationmyelodysplastic syndrome MDS MDS MDS
myelodysplastic syndrome MDS MDS 15 10 3 2004 15 MDS 400 2 65 61 70 MDS MDS 1 1 2 3 3 4 1 4 2 3 4 MDS 1982 Bennett French- American-BritishFAB 1 2 WHO 1999 3 2001 4 2002 Vardiman MDS 5 2WHO FAB refractory
More informationUPDATE Autologous Stem Cell Transplantation for Lymphoma and Myeloma
UPDATE Autologous Stem Cell Transplantation for Lymphoma and Myeloma Supported by a grant from Supported by a grant from UPDATE Autologous Stem Cell Transplantation for Lymphoma and Myeloma Jonathan W.
More informationRUNX1 and FPD/AML Translational Research. The Leukemia and Lymphoma Society / Babich Family Foundation Partnership. September 2016
www.lls.org www.runx1.com RUNX1 and FPD/AML Translational Research The Leukemia and Lymphoma Society / Babich Family Foundation Partnership September 2016 Prepared by L. Greenberger, PhD Chief Scientific
More informationBosulif. Bosulif (bosutinib) Description
Federal Employee Program 1310 G Street, N.W. Washington, D.C. 20005 202.942.1000 Fax 202.942.1125 5.21.22 Section: Prescription Drugs Effective Date: April 1,2018 Subject: Bosulif Page: 1 of 5 Last Review
More informationHematologic Malignancies. Eunice S. Wang MD Leukemia Service, Department of Medicine Roswell Park Cancer Institute SUNY-UB School of Medicine
Hematologic Malignancies Eunice S. Wang MD Leukemia Service, Department of Medicine Roswell Park Cancer Institute SUNY-UB School of Medicine Blood cancers are normal blood cells gone bad Jordan C et
More informationBlast Phase Chronic Myelogenous Leukemia
Blast Phase Chronic Myelogenous Leukemia Benjamin Powers, MD; and Suman Kambhampati, MD The dramatic improvement in survival with tyrosine kinase inhibitors has not been demonstrated in the advanced blast
More informationHypereosinophili c syndrome
Hypereosinophili c syndrome Eosinophilia Eosinophilia is commonly defined as an elevated percentage of eosinophils, with an absolute eosinophil count > 500 cells per cubic millimeter Secondary Primary
More informationChronic Lymphocytic Leukemia Update. Learning Objectives
Chronic Lymphocytic Leukemia Update Ashley Morris Engemann, PharmD, BCOP, CPP Clinical Associate Adult Stem Cell Transplant Program Duke University Medical Center August 8, 2015 Learning Objectives Recommend
More informationImpact of Comorbidity on Quality of Life and Clinical Outcomes in MDS
Current Therapeutic and Biologic Advances in MDS A Symposium of The MDS Foundation ASH 2014 Impact of Comorbidity on Quality of Life and Clinical Outcomes in MDS Peter Valent Medical University of Vienna
More informationPersonalized Therapy for Acute Myeloid Leukemia. Patrick Stiff MD Loyola University Medical Center
Personalized Therapy for Acute Myeloid Leukemia Patrick Stiff MD Loyola University Medical Center 708-327-3216 Major groups of Mutations in AML Targets for AML: Is this Achievable? Chronic Myeloid Leukemia:
More informationAtomic Bomb and Leukemia ICHIMARU M., TOMONAGA M., AMENOMORI T. AND MATSUO T.
Atomic Bomb and Leukemia ICHIMARU M., TOMONAGA M., AMENOMORI T. AND MATSUO T. Department of Hematology, Atomic Disease Institute, Nagasaki University School of Medicine, Nagasaki, Japan (Received December
More informationStem Cells And The Future of Regenerative Medicine. Dipnarine Maharaj, M. D., FACP
Stem Cells And The Future of Regenerative Medicine Dipnarine Maharaj, M. D., FACP The following potential conflict of interest relationships are germane to my presentation. Employment: South Florida Bone
More informationSupplementary Materials for
Supplementary Materials for A Clinical Trial for Patients with Acute Myeloid Leukemia or Myelodysplastic Syndromes Not Eligible for Standard Clinical Trials Table of Contents Content Page Supplementary
More informationGleevec. Gleevec (imatinib) Description
Federal Employee Program 1310 G Street, N.W. Washington, D.C. 20005 202.942.1000 Fax 202.942.1125 5.21.74 Subject: Gleevec Page: 1 of 6 Last Review Date: June 24, 2016 Gleevec Description Gleevec (imatinib)
More informationCase Workshop of Society for Hematopathology and European Association for Haematopathology
Case 148 2007 Workshop of Society for Hematopathology and European Association for Haematopathology Robert P Hasserjian Department of Pathology Massachusetts General Hospital Boston, MA Clinical history
More informationMyelodyplastic Syndromes Paul J. Shami, M.D.
Myelodyplastic Syndromes Paul J. Shami, M.D. Professor of Hematology, University of Utah Member, Huntsman Cancer Institute Objectives Define Myelodysplastic Syndromes (MDS) Explain how MDS are diagnosed
More informationChanges to the 2016 WHO Classification for the Diagnosis of MDS
Changes to the 2016 WHO Classification for the Diagnosis of MDS Welcome to Managing MDS. I am Dr. Ulrich Germing, and today, I will provide highlights from the 14th International Symposium on MDS in Valencia,
More informationNews Release. Title Integrated molecular profiling of juvenile myelomonocytic leukemia
News Release Title Integrated molecular profiling of juvenile myelomonocytic leukemia Key Points We identified ALK/ROS1 tyrosine kinase fusions (DCTN1-ALK, RANBP2-ALK, and TBL1XR1-ROS1) in patients with
More informationAcute Promyelocytic Leukemia with i(17)(q10)
CASE REPORT Acute Promyelocytic Leukemia with i(17)(q10) Junki Inamura 1, Katsuya Ikuta 2, Nodoka Tsukada 1, Takaaki Hosoki 1, Motohiro Shindo 2 and Kazuya Sato 1 Abstract We herein report a rare chromosomal
More informationAdvances in haematological malignancies focus on lymphoid disease
Advances in haematological malignancies focus on lymphoid disease Dr Kylie Mason MBBS PhD FRACP FRCPA Haematologist Bone marrow Transplant Physician Clinician Scientist The Royal Melbourne Hospital The
More informationAcknowledgements. Department of Hematological Malignancy and Cellular Therapy, University of Kansas Medical Center
The Addition of Extracorporeal Photopheresis (ECP) to Tacrolimus and Methotrexate to Prevent Acute and Chronic Graft- Versus Host Disease in Myeloablative Hematopoietic Cell Transplant (HCT) Anthony Accurso,
More informationBMTCN Review Course Basic Concepts and Indications for Transplantation How the Experts Treat Hematologic Malignancies Las Vegas, NV, March 10, 2016
BMTCN Review Course Basic Concepts and Indications for Transplantation How the Experts Treat Hematologic Malignancies Las Vegas, NV, March 10, 2016 David Rice, PhD, RN, NP Director, Professional Practice
More informationWhat s a Transplant? What s not?
What s a Transplant? What s not? How to report the difference? Daniel Weisdorf MD University of Minnesota Anti-cancer effects of BMT or PBSCT [HSCT] Kill the cancer Save the patient Restore immunocompetence
More informationMedical Benefit Effective Date: 07/01/12 Next Review Date: 03/13 Preauthorization* Yes Review Dates: 04/07, 05/08, 03/10, 03/11, 03/12
Hematopoietic Stem-Cell Transplantation for Chronic Myelogenous (80130) Medical Benefit Effective Date: 07/01/12 Next Review Date: 03/13 Preauthorization* Yes Review Dates: 04/07, 05/08, 03/10, 03/11,
More informationup to date 8F Non-Hodgkin's Lymphoma RIST RIST ICT
2 up to date 16 2 6 17:45 5F up to date 2 16 2 27 1900 8F Non-Hodgkin's Lymphoma RIST 2 16 4 23 1830 4 RIST 3 16 5 28 1900 20 CML 1 3 16 7 28 1730 5 3 16 10 18 1830 5 AML RIST FDG-PET follow up 2 Infection
More informationDIAGNOSIS AND TREATMENT OF WALDENSTRÖM S MACROGLOBULINAEMIA IN THE NETHERLANDS. Monique Minnema UMC Utrecht
DIAGNOSIS AND TREATMENT OF WALDENSTRÖM S MACROGLOBULINAEMIA IN THE NETHERLANDS Monique Minnema UMC Utrecht Organisation of hematological care in the Netherlands Intensive chemotherapy, including acute
More informationAllogeneic Hematopoietic Stem-Cell Transplantation for Myelodysplastic Syndromes and Myeloproliferative Neoplasms. Policy Specific Section:
Medical Policy Allogeneic Hematopoietic Stem-Cell Transplantation for Myelodysplastic Syndromes and Myeloproliferative Type: Medical Necessity and Investigational / Experimental Policy Specific Section:
More informationBeyond the CBC Report: Extended Laboratory Testing in the Evaluation for Hematologic Neoplasia Disclosure
Beyond the CBC Report: Extended Laboratory Testing in the Evaluation for Hematologic Neoplasia Disclosure I am receiving an honorarium from Sysmex for today s presentation. 1 Determining the Etiology for
More informationSupervisor: Prof. Dr. P Vandenberghe Dr. C Brusselmans
Contribution of molecular diagnosis in eosinophilia/hypereosinophilia Eosinophilia Hypereosinophilia Hypereosinophilic syndrome Immune mediated hypereosinophilia Chronic eosinophilic leukemia (NOS)/ Idiopathic
More informationNature Genetics: doi: /ng Supplementary Figure 1
Supplementary Figure 1 MSI2 interactors are associated with the riboproteome and are functionally relevant. (a) Coomassie blue staining of FLAG-MSI2 immunoprecipitated complexes. (b) GO analysis of MSI2-interacting
More informationMolecular Hematopathology Leukemias I. January 14, 2005
Molecular Hematopathology Leukemias I January 14, 2005 Chronic Myelogenous Leukemia Diagnosis requires presence of Philadelphia chromosome t(9;22)(q34;q11) translocation BCR-ABL is the result BCR on chr
More informationCorrespondence should be addressed to Anas Khanfar;
Case Reports in Oncological Medicine, Article ID 949515, 4 pages http://dx.doi.org/10.1155/2014/949515 Case Report Durable Hematological and Major Cytogenetic Response in a Patient with Isolated 20q Deletion
More information소아에서발생한 Blastic Plasmacytoid Dendritic Cell Neoplasm 1 예
Clinical Pediatric Hematology-Oncology Volume 22 ㆍ Number 2 ㆍ October 2015 CASE REPORT 소아에서발생한 Blastic Plasmacytoid Dendritic Cell Neoplasm 1 예 박경미 1 ㆍ양유진 1 ㆍ서정호 1 ㆍ신동훈 2 ㆍ임영탁 1 부산대학교의과대학 1 소아과학교실, 2 병리학교실
More informationChronic myelomonocytic leukemia. Lymphoma Tumor Board. May 26, 2017
Chronic myelomonocytic leukemia Lymphoma Tumor Board May 26, 2017 Myeloproliferative Neoplasms CMML has an estimated incidence of less than 1 per 100,000 persons per year Myeloproliferative neoplasms (MPN)
More informationIntroduction to Hematopoietic Stem Cell Transplantation
Faculty Disclosures Introduction to Hematopoietic Stem Cell Transplantation Nothing to disclose Jeanne McCarthy-Kaiser, PharmD, BCOP Clinical Pharmacist, Autologous Stem Cell Transplant/Long- Term Follow-Up
More informationBlood Cancers. Blood Cells. Blood Cancers: Progress and Promise. Bone Marrow and Blood. Lymph Nodes and Spleen
Blood Cancers: Progress and Promise Mike Barnett & Khaled Ramadan Division of Hematology Department of Medicine Providence Health Care & UBC Blood Cancers Significant health problem Arise from normal cells
More informationHEMATOLOGIC MALIGNANCIES BIOLOGY
HEMATOLOGIC MALIGNANCIES BIOLOGY Failure of terminal differentiation Failure of differentiated cells to undergo apoptosis Failure to control growth Neoplastic stem cell FAILURE OF TERMINAL DIFFERENTIATION
More informationMolecular Markers. Marcie Riches, MD, MS Associate Professor University of North Carolina Scientific Director, Infection and Immune Reconstitution WC
Molecular Markers Marcie Riches, MD, MS Associate Professor University of North Carolina Scientific Director, Infection and Immune Reconstitution WC Overview Testing methods Rationale for molecular testing
More informationObjectives. Morphology and IHC. Flow and Cyto FISH. Testing for Heme Malignancies 3/20/2013
Molecular Markers in Hematologic Malignancy: Ways to locate the needle in the haystack. Objectives Review the types of testing for hematologic malignancies Understand rationale for molecular testing Marcie
More informationChronic myeloid leukemia (CML)
Bioscientia Int. Support Services Dept. Konrad-Adenauer-Strasse 17 55218 Ingelheim Germany Phone 49(0)6132-781-203 49(0)6132-781-224 49(0)6132-781-165 Fax 49(0)6132-781-236 int.support@bioscientia.com
More informationNucleic Acid Testing - Oncology. Molecular Diagnosis. Gain/Loss of Nucleic Acid. Objectives. MYCN and Neuroblastoma. Molecular Diagnosis
Nucleic Acid Testing - Oncology Molecular Diagnosis Nucleic acid based testing in Oncology Gross alterations in DNA content of tumors (ploidy) Gain/Loss of nucleic acids Markers of Clonality Oncogene/Tumor
More informationLeukine. Leukine (sargramostim) Description
Federal Employee Program 1310 G Street, N.W. Washington, D.C. 20005 202.942.1000 Fax 202.942.1125 5.85.08 Subject: Leukine Page: 1 of 5 Last Review Date: September 15, 2017 Leukine Description Leukine
More informationMolecular Diagnosis. Nucleic acid based testing in Oncology
Molecular Diagnosis Nucleic acid based testing in Oncology Objectives Describe uses of NAT in Oncology Diagnosis, Prediction, monitoring. Genetics Screening, presymptomatic testing, diagnostic testing,
More informationInnate Immunity Dysregulation in Myelodysplastic Syndromes. CONTRACTING ORGANIZATION: University of Texas MD Anderson Cancer Center Houston, TX 77030
AWARD NUMBER: W81XWH-12-1-0221 TITLE: Innate Immunity Dysregulation in Myelodysplastic Syndromes PRINCIPAL INVESTIGATOR: Yue Wei CONTRACTING ORGANIZATION: University of Texas MD Anderson Cancer Center
More informationPreface In recent years, the pathogenesis of hematological disorders in children has been clarified, which has led to remarkable progress in the treatment outcome for these disorders. In particular, molecular
More informationSession 5. Pre-malignant clonal hematopoietic proliferations. Chairs: Frank Kuo and Valentina Nardi
Session 5 Pre-malignant clonal hematopoietic proliferations Chairs: Frank Kuo and Valentina Nardi Pre-malignant clonal hematopoietic proliferations Clonal LYMPHOID proliferations: - Monoclonal gammopathy
More informationLeukine. Leukine (sargramostim) Description
Federal Employee Program 1310 G Street, N.W. Washington, D.C. 20005 202.942.1000 Fax 202.942.1125 Subject: Leukine Page: 1 of 6 Last Review Date: November 30, 2018 Leukine Description Leukine (sargramostim)
More informationCase report Leukemia in donor cells after allogeneic hematopoietic stem cell transplant
(2002) 29, 999 1003 2002 Nature Publishing Group All rights reserved 0268 3369/02 $25.00 www.nature.com/bmt Case report Leukemia in donor cells after allogeneic hematopoietic stem cell transplant CG Brunstein
More informationStem cells and Cancer. John Glod. December 2, 2009
Stem cells and Cancer John Glod Lehigh University Lehigh University December 2, 2009 The Tumor Microenvironment Littlepage et al Cancer Cell 2005 Cancer Stem Cells A small group of cells within the larger
More informationStandard risk ALL (and its exceptions
Mahshid Mehdizadeh Standard risk ALL (and its exceptions WBC at diagnosis below 50 109/L - age 1 year - no central nervous system (CNS) involvement - ETV6/RUNX1 positivity - MRD at Day
More informationTreating Higher-Risk MDS. Case presentation. Defining higher risk MDS. IPSS WHO IPSS: WPSS MD Anderson PSS
Treating Higher-Risk MDS Eyal Attar, M.D. Massachusetts General Hospital Cancer Center eattar@partners.org 617-724-1124 Case presentation 72 year old man, prior acoustic neuroma WBC (X10 3 /ul) 11/08 12/08
More informationTrends in Hematopoietic Cell Transplantation. AAMAC Patient Education Day Oct 2014
Trends in Hematopoietic Cell Transplantation AAMAC Patient Education Day Oct 2014 Objectives Review the principles behind allogeneic stem cell transplantation Outline the process of transplant, some of
More informationMyelodysplastic Syndromes Myeloproliferative Disorders
Myelodysplastic Syndromes Myeloproliferative Disorders Myelodysplastic Syndromes characterized by maturation defects that are associated with ineffective hematopoiesis and a high risk of transformation
More informationEHA 2017 Abstracts: 4 Abstracts ( 1 Oral Presentation, 2 EPosters, 1 Publication)
EHA 2017 Abstracts: 4 Abstracts ( 1 Oral Presentation, 2 EPosters, 1 Publication) ORAL RIGOSERTIB COMBINED WITH AZACITIDINE IN PATIENTS WITH ACUTE MYELOID LEUKEMIA (AML) AND MYELODYSPLASTIC SYNDROMES (MDS):
More informationLeukine. Leukine (sargramostim) Description
Federal Employee Program 1310 G Street, N.W. Washington, D.C. 20005 202.942.1000 Fax 202.942.1125 5.10.08 Subject: Leukine Page: 1 of 6 Last Review Date: March 13, 2014 Leukine Description Leukine (sargramostim)
More informationCurable cancers: Progress in Oncology. Prof.Dilip Kumar Dhar Princicipal & Professor of Medicine MH Samorita Hospital & Medical College, Dhaka.
Curable cancers: Progress in Oncology Prof.Dilip Kumar Dhar Princicipal & Professor of Medicine MH Samorita Hospital & Medical College, Dhaka. Introduction Cancer is one of the leading causes of morbidity
More informationCHALLENGING CASES PRESENTATION
CHALLENGING CASES PRESENTATION Michael C. Wiemann, MD, FACP Program Co-Chair and Vice President Indy Hematology Education President, Clinical St. John Providence Physician Network Detroit, Michigan 36
More informationMP BCR-ABL1 Testing in Chronic Myelogenous Leukemia and Acute Lymphoblastic Leukemia
Medical Policy BCBSA Ref. Policy: 2.04.85 Last Review: 10/18/2018 Effective Date: 10/18/2018 Section: Medicine Related Policies 8.01.30 Hematopoietic Cell Transplantation for Chronic Myelogenous Leukemia
More informationStem cells. -Dr Dinesh Bhurani, MD, DM, FRCPA. Rajiv Gandhi Cancer Institute, Delhi, -Director, Department of Haematology and BMT
Stem cells -Dr Dinesh Bhurani, MD, DM, FRCPA -Director, Department of Haematology and BMT Rajiv Gandhi Cancer Institute, Delhi, Flow of presentation Update on stem cell uses Haematopoietic stem cell transplantation
More informationOrbital MALT Lymphoma after Autologous Stem Cell Transplantation for Follicular Lymphoma as Relapse of Diffuse Large B-Cell Lymphoma
J Clin Exp Hematop Vol. 56, No. 3, March 2017 Case Study Orbital MALT Lymphoma after Autologous Stem Cell Transplantation for Follicular Lymphoma as Relapse of Diffuse Large B-Cell Lymphoma Toshihiko Matsuo,
More informationMast Cell Disease Case 054 Session 7
Mast Cell Disease Case 054 Session 7 Rodney R. Miles, M.D., Ph.D. Lauren B. Smith, M.D. Cem Akin, M.D. Diane Roulston,, Ph.D. Charles W. Ross, M.D. Departments of Pathology and Internal Medicine University
More informationRegence. Next Review: 08/2019 Last Review: 08/2018 Medicare Link(s) Revised: 10/01/2018 IMPORTANT REMINDER
Regence Medicare Advantage Policy Manual Policy ID: M-TRA45 Stem Cell / Bone Marrow Transplants Published: 10/01/2018 Next Review: 08/2019 Last Review: 08/2018 Medicare Link(s) Revised: 10/01/2018 IMPORTANT
More information